Details of the Drug

General Information of Drug (ID: DM9MF08)

Drug Name
OBP-301
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 1/2 [1]
Head and neck cancer 2D42 Phase 1/2 [1]
Liver cancer 2C12 Phase 1/2 [1]
Cross-matching ID
TTD ID
D0D8ZK
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Telomerase reverse transcriptase (TERT) TTUJFD0 TERT_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Breast cancer
ICD Disease Classification 2C60-2C65
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Telomerase reverse transcriptase (TERT) DTT TERT 8.59E-10 -0.08 -0.33
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02293850) Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma. U.S. National Institutes of Health.
2 Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):285-92.